People: ARIAD Pharmaceuticals Inc (ARIA.O)

Summary

Name	Age	Since	Current Position
Harvey Berger	63	2004	Chairman of the Board, President, Chief Executive Officer
Edward Fitzgerald	58	2010	Chief Financial Officer, Executive Vice President, Treasurer
Raymond Keane	54	2009	Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
David Berstein	61	2008	Senior Vice President, Chief Intellectual Property Officer
Daniel Bollag	52	2009	Senior Vice President - Regulatory Affairs and Quality
Maria Cantor	45	2012	Senior Vice President - Corporate Affairs
Pierre Dodion	58	2012	Senior Vice President - Corporate Development and Operations
Martin Duvall	50	2011	Senior Vice President - Commercial Operations
Frank Haluska	54	2012	Senior Vice President - Clinical Research and Development and Chief Medical Officer
Timothy Clackson	48	2010	President - Research and Development, Chief Scientific Officer
Athanase Lavidas	65	2008	Lead Independent Director
Jay LaMarche	66	2000	Independent Director
Massimo Radaelli	55	2008	Independent Director
Norbert Riedel	55	2011	Independent Director
Robert Whelan	61	2010	Independent Director
Wayne Wilson	64	2008	Independent Director
Kendra Adams			Director - Investor Relations

» Insider Trading

Biographies

Name	Description
Harvey Berger	Dr. Harvey J. Berger, M.D., is Chairman of the Board, President, Chief Executive Officer of Ariad Pharmaceuticals, Inc. He is principal founder and has served as Chairman of the Board and Chief Executive Officer since April 1991. He served as President from April 1991 to September 2003 and from December 2004 to present. He is chair of the Executive Committee. From 1986 to 1991, Dr. Berger held a series of executive management positions at Centocor, Inc., a biotechnology company, including Executive Vice President and President, Research and Development Division. He has also held senior academic and administrative appointments at Emory University, Yale University and the University of Pennsylvania and was an Established Investigator of the American Heart Association. Dr. Berger currently serves as a member of the Dean’s Council of Yale School of Medicine. Dr. Berger received his A.B. degree in Biology from Colgate University and his M.D. degree from Yale University School of Medicine. He obtained further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.
Edward Fitzgerald	Mr. Edward M. Fitzgerald is Chief Financial Officer, Executive Vice President, Treasurer of Ariad Pharmaceuticals, Inc. since June 2010. Previously, he served as Senior Vice President, Chief Financial Officer and Treasurer from May 2002 to June 2010. Mr. Fitzgerald received his B.S. degree in accounting and M.B.A. degree in finance from Babson College.
Raymond Keane	Mr. Raymond T. Keane, Esquire, is Senior Vice President, General Counsel, Secretary and Chief Compliance Officer of Ariad Pharmaceuticals, Inc. since January 2009. Previously, he served as Vice President, General Counsel and Chief Compliance Officer from May 2008 to January 2009. From 2003 to 2008, Mr. Keane led the Global Commercialization legal team at Bristol-Myers Squibb Company. He received his J.D. degree from Fordham University School of Law and his B.A. degree in Economics from Fordham University.
David Berstein	Mr. David L. Berstein, Esquire, is Senior Vice President and Chief Intellectual Property Officer of Ariad Pharmaceuticals, Inc. since May 2008. Previously, he served as Senior Vice President and Chief Patent Counsel from June 2003 to June 2007.
Daniel Bollag	Dr. Daniel M. Bollag, Ph.D. is Senior Vice President - Regulatory Affairs and Quality of Ariad Pharmaceuticals, Inc. since January 2009. He previously was Vice President, Regulatory Affairs for Genzyme Corporation, a biotechnology company, from 2006 to 2008.
Maria Cantor	Ms. Maria E. Cantor is Senior Vice President - Corporate Affairs of Ariad Pharmaceuticals Inc. since January 2012. Previously, she served as Vice President, Corporate Communications and Investor Relations since July 2008. Ms. Cantor held several positions of increasing responsibility at Genzyme Corporation from 2001 to 2008, most recently serving as Senior Director, Corporate Communications.
Pierre Dodion	Dr. Pierre F. Dodion, M.D., M.B.A., is Senior Vice President - Corporate Development and Operations of Ariad Pharmaceuticals, Inc. since February 2012. He was Senior Vice President, Corporate Development from July 2010 to January 2012. Previously, he served as Senior Vice President and Chief Medical Officer from April 2008 to June 2010 and as Senior Vice President, Oncology from June 2007 to April 2008.
Martin Duvall	Mr. Martin J. Duvall is Senior Vice President - Commercial Operations of Ariad Pharmaceuticals, Inc., since September 2011. Previously, he served as Senior Vice President and General Manager of Merck and Company’s global oncology franchise. From 2009 to 2010, Mr. Duvall led global marketing and commercial operations at Abraxis Bioscience, Inc. From 2004 to 2009, Mr. Duvall held roles of commercial operations, commercial development and oncology strategy for MGI Pharma, Inc. and its acquirer, Eisai Pharmaceuticals.
Frank Haluska	Dr. Frank G. Haluska, M.D., Ph.D., is Senior Vice President - Clinical Research and Development and Chief Medical Officer of Ariad Pharmaceuticals, Inc., since January 2012. He has held the position of Vice President and Chief Medical Officer since June 2010. Previously, he served as Vice President, Clinical Affairs from May 2009 to June 2010, Vice President, Clinical Research from July 2008 to May 2009, and Senior Medical Director from October 2007 to July 2008. He received his M.D. degree and Ph.D. degree from the University of Pennsylvania School of Medicine and A.B. degree from Harvard University.
Timothy Clackson	Dr. Timothy P. Clackson, Ph.D., is President - Research and Development, Chief Scientific Officer of Ariad Pharmaceuticals, Inc. since June 2010. Previously, he served as Senior Vice President and Chief Scientific Officer from September 2003 to June 2010. Dr. Clackson received his B.A. degree in Biochemistry from the University of Oxford, and his Ph.D. degree in Biology from the University of Cambridge for research conducted at the MRC Laboratory of Molecular Biology that included the development of antibody phage display technology.
Athanase Lavidas	Dr. Athanase Lavidas, Ph.D., is Lead Independent Director of Ariad Pharmaceuticals, Inc. since November 2008. He has been the Chairman and Chief Executive Officer of the Lavipharm Group, a pharmaceutical, cosmetics and consumer health-products company headquartered in Greece, since 1976. Dr. Lavidas is also Chairman of the Greece-U.S. Business Council and Chairman of SEV Business Council for International Activities, the international arm of the Hellenic Federation of Industries and Enterprises (SEV). Dr. Lavidas has been a member of Board since September 2003 and has served as lead director since November 2008. He is chair of the Nominating and Corporate Governance Committee and a member of the Executive Committee and the Compensation Committee. Dr. Lavidas received his B.S. and M.S. in chemistry from the University of Munich, his M.B.A. from the Institut Superieur de Marketing et de Management in Paris and his Ph.D. degree in pharmaceutical chemistry from the University of Athens.
Jay LaMarche	Mr. Jay R. LaMarche is Independent Director of Ariad Pharmaceuticals, Inc. since January 1992. He has served the company for over twenty years as a director and in executive leadership positions including Chief Financial Officer and Treasurer from January 1992 to November 2000. Mr. LaMarche was Executive Vice President from March 1997 to November 2000 and Senior Vice President, Finance from January 1992 to February 1997. Prior to joining ARIAD, he was Chief Financial Officer and a director of ChemDesign Corporation, a chemicals manufacturer. Previously, Mr. LaMarche was an audit partner with Deloitte Haskins & Sells, a public accounting firm. Mr. LaMarche also served as an officer in the United States Navy. Mr. LaMarche received his B.B.A. degree in Public Accountancy from the University of Notre Dame.
Massimo Radaelli	Dr. Massimo Radaelli, Ph.D., is Independent Director of Ariad Pharmaceuticals, Inc. since October 2008. He is the President and Chief Executive Officer of Noventia Pharma, a specialty pharmaceutical company focused on orphan drugs for the treatment of rare diseases, in particular for the central nervous system and respiratory system. Prior to joining Noventia in May 2009, Dr. Radaelli was President and Chief Executive Officer of Dompé International SA, the international pharmaceutical company of the Dompé Group. He joined Dompé in 1996 as director of corporate business development. Dr. Radaelli is also Executive Chairman of Bioakos Pharma Laboratories, a specialty pharmaceuticals company concentrated in the fields of gynecology, dermatology, ear, nose and throat and pediatrics and a director of Arriani International, SA, the international subsidiary of Arriani Pharmaceuticals, a pharmaceutical company in southeastern Europe. Since October 2012, Dr. Radaelli has served as Chairman of Zarzatech Inc., as well as President of its European subsidiary, Zarzatech Sàrl. Dr. Radaelli is a member of the Italian Society of Pharmacology and has been awarded the highest ranking honor of the Italian Republic by the President and Prime Minister of Italy for merit acquired in the fields of science and biopharma and for his commitment to patients with rare diseases and unmet medical needs. Dr. Radaelli received a University Degree in pharmaceutical sciences and a Ph.D. in clinical pharmacology from the University of Milan and an Executive Master of Business from Bocconi University of Milan.
Norbert Riedel	Dr. Norbert G. Riedel, Ph.D., is Independent Director of Ariad Pharmaceuticals, Inc. He was Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company from March 2001 until January 2013. From 1998 to 2001, Dr. Riedel served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development at Baxter’s bioscience business. Prior to joining Baxter, from 1996 to 1998, he was head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi-Aventis, a global pharmaceutical company. Previously, he held a series of scientific management positions at Hoechst-Marion Roussel and Hoechst AG. Dr. Riedel has been a member of the Supervisory Board of MediGene AG, since 2003. He is a member of the Board of Directors of the Illinois Biotechnology Industry Organization and also serves on the Advisory Board of Northwestern University’s Kellogg School of Management Center for Biotechnology, and the McCormick School of Engineering. Most recently, he was appointed by Illinois Governor Pat Quinn to the newly formed Illinois Innovation Council. From 1999 to 2010, Dr. Riedel was a member of the board of directors of Oscient Pharmaceuticals Corporation & Genome Therapeutics Corporation. Dr. Riedel was a postdoctoral fellow at Harvard University from 1984 to 1987 and an Assistant Professor and Associate Professor of medicine and biochemistry at Boston University School of Medicine from 1987 to 1991, is an adjunct professor at Boston University School of Medicine, and an adjunct professor of Medicine at Northwestern University’s Feinberg School of Medicine and was a visiting professor at Massachusetts Institute of Technology in 1992. In 2009, Dr. Riedel was elected as a member of the Austrian Academy of Sciences. Dr. Riedel received his Diploma in biochemistry from the University of Frankfurt in 1981 and his Ph.D. in biochemistry from the University of Frankfurt in 1983.
Robert Whelan	Mr. Robert M. Whelan, Jr., is Independent Director of Ariad Pharmaceuticals, Inc. He has nearly forty years of investment banking experience working predominantly with high technology and healthcare companies. He has been the President of Whelan & Company, LLC, providing business and financial consulting and strategic services to a broad range of companies, since 2001. From 2001 to 2005, Mr. Whelan served as Managing Director of Valuation Perspectives, Inc., a consulting firm. Prior to that, he held a number of senior-level positions at various investment banking and brokerage firms. Mr. Whelan was Vice Chairman of Prudential Volpe Technology Group, the technology investment banking and research division of Prudential Securities. Prior to Prudential Volpe, he was Chief Operating Officer, Managing Director, board member and Head of Investment Banking of Volpe Brown Whelan & Company, a private technology and healthcare investment banking, brokerage and asset management firm. Volpe Brown Whelan & Company was acquired by Prudential Securities in 1999. From 2008 to 2009, Mr. Whelan was a Fellow at the Harvard University Advanced Leadership Initiative, an innovative year-long program aimed at providing a rigorous educational curriculum for exceptional leaders who have reached the height of their professions and are seeking to contribute their skills to solve global social problems. Mr. Whelan currently serves as chairman of the board of directors of Aspen Technology, Inc., a publicly traded provider of software and services for the process industries based in Burlington, Massachusetts. Mr. Whelan received a B.A. in history from Dartmouth College and a M.B.A. from Stanford University Graduate School of Business.
Wayne Wilson	Mr. Wayne Wilson is Independent Director of Ariad Pharmaceuticals, Inc. since October 2008. He has over thirty years of business, financial, and accounting experience. He has been an independent business advisor since 2002. From 1995 to 2002, he served in various roles, including as President, Chief Operating Officer, and Chief Financial Officer, at PC Connection, Inc. From 1986 to 1995, Mr. Wilson was a partner in the assurance and advisory services practice of Deloitte & Touche LLP. Mr. Wilson has been a member of the Board since October 2008. He is chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee and the Executive Committee. Mr. Wilson is also a member of the boards of directors of FairPoint Communications, Inc., a telecommunications company, Hologic, Inc., a medical diagnostics and device company focusing on women’s health, and Edgewater Technology, Inc., a technology management consulting firm. He previously served as a director of Cytyc Corporation, a medical diagnostics and device company. Mr. Wilson received an A.B. degree in political science from Duke University and an M.B.A. from the University of North Carolina at Chapel Hill.
Kendra Adams

Basic Compensation

Name	Fiscal Year Total
Harvey Berger	5,986,840
Edward Fitzgerald	1,946,620
Raymond Keane	--
David Berstein	744,434
Daniel Bollag	779,877
Maria Cantor	1,697,560
Pierre Dodion	558,946
Martin Duvall	1,157,540
Frank Haluska	1,709,760
Timothy Clackson	2,376,080
Athanase Lavidas	--
Jay LaMarche	223,592
Massimo Radaelli	--
Norbert Riedel	--
Robert Whelan	--
Wayne Wilson	--
Kendra Adams	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Harvey Berger	774,046	1,638,873
Edward Fitzgerald	343,000	1,331,750
Raymond Keane	0	0
David Berstein	409,571	471,691
Daniel Bollag	0	0
Maria Cantor	19,978	261,844
Pierre Dodion	0	0
Martin Duvall	0	0
Frank Haluska	10,500	139,182
Timothy Clackson	455,738	3,414,268
Athanase Lavidas	0	0
Jay LaMarche	286,357	1,107,673
Massimo Radaelli	0	0
Norbert Riedel	0	0
Robert Whelan	0	0
Wayne Wilson	0	0
Kendra Adams	0	0

Insider Trading

Name	Shares Traded	Price
BERGER HARVEY J	2,700	$18.14
BERGER HARVEY J	37,098	$18.22
BERGER HARVEY J	2,700	$18.00
BERGER HARVEY J	50,000	$18.01
BERGER HARVEY J	100,000	$18.01
BERGER HARVEY J	5,400	$18.00
KEANE RAYMOND T	2,583	$18.05
CLACKSON TIMOTHY P	6,500	$18.04
BERSTEIN DAVID L	2,400	$18.05
CANTOR MARIA E	4,250	$18.04
HALUSKA FRANK G	3,400	$18.04
DODION PIERRE F	2,400	$18.04
BOLLAG DANIEL M	2,400	$18.05
FITZGERALD EDWARD M	5,200	$18.04
CLACKSON TIMOTHY P	13,000	$0.00
BERGER HARVEY J	19,688	$18.30
FITZGERALD EDWARD M	13,000	$0.00
DODION PIERRE F	6,000	$0.00
KEANE RAYMOND T	5,166	$0.00
BOLLAG DANIEL M	6,000	$0.00
HALUSKA FRANK G	8,500	$0.00
BERGER HARVEY J	41,666	$0.00
CANTOR MARIA E	8,500	$0.00
BERSTEIN DAVID L	6,000	$0.00
FITZGERALD EDWARD M	12,933	$18.75

» Full list on Insider Trading

People: ARIAD Pharmaceuticals Inc (ARIA.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: